Samsung invests in biosimilars

South Korea's Samsung Electronics will invest about 500 billion won (R3.2 billion) in the biotech medicine business, quoting a top policymaker, reports Reuters.

The nation's economy minister, Lee Youn-ho, said Samsung, maker of memory chips and flat-screen TVs, would spend the amount over the next five years on the biosimilar business.

Biosimilars are versions of biopharmaceuticals whose patents have expired.

IntegraCare Holdings has selected Homecare Homebase, a software development company, to deploy a Web-based, software automation solution across its 27 home health and five hospice branches, states TMCnet.

IntegraCare, with an average daily census of 1 900 patients and growing, is a provider of homecare, hospice and palliative care to communities in north central and west Texas.

"We needed an automation solution that would allow us to deploy a common set of clinical, financial and operational processes across our current and prospective network of branches," said Chris Gerard, CEO of IntegraCare, in a statement.

Worldwide spam volumes are being further driven by an increase in online pharmacy messages, according to Computing.co.uk.

According to a recent report from security firm Marhal8E6, 90% of e-mail traffic is due to spam messages. Meanwhile, the company estimates that of the total spam load, 75% of that spam is for online pharmaceuticals.

Of the total spam load, Marshal8E6 researchers found that much of the spam traffic was driven by botnets. A recent report from MessageLabs reported similar findings.